The ANKRD26 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ANKRD26 gene in the A-549 human lung adenocarcinoma cell line. This heterogeneous pool of edited cells harbors distinct CRISPR-mediated disruptions within the ANKRD26 locus, providing a loss-of-function model that avoids artifacts arising from single-cell cloning and captures population-level genetic perturbation effects. The product is designed for researchers investigating ANKRD26-dependent transcriptional regulation and its implications in lung adenocarcinoma biology, without assumptions of monoclonality or biallelic inactivation.
A-549 cells are an adherent, epithelial-like line originally established from explanted lung tissue of a 58-year-old Caucasian male with lung adenocarcinoma. This widely used model system retains features of type II pneumocytes and carries activating KRAS mutations alongside TP53 alterations, making it genetically relevant for studying adenocarcinoma signaling and therapeutic resistance. The cellular background supports a broad array of functional assays, including proliferation, colony formation, migration, invasion, and drug sensitivity testing, and is compatible with common molecular biology and imaging techniques.
ANKRD26 encodes a transcriptional repressor that binds DNA and recruits HDAC-containing corepressor complexes, particularly HDAC1 and HDAC2, to silence target gene expression. It functions within a network regulated by upstream factors such as THPO, MPL, RUNX1, GATA1, and FLI1, while directly repressing downstream targets including MPL, MYC, and BCL2L1. ANKRD26 intersects with the thrombopoietin?CJAK2?CSTAT3 axis, and influences MAPK1 and AKT1 phosphorylation cascades, thereby coupling receptor-mediated signals to transcriptional repression of proliferative and anti-apoptotic programs. Its role as a potential tumor suppressor is underscored by its involvement in megakaryopoiesis and thrombopoiesis, and its dysregulation in thrombocytopenia 2 and myeloid malignancies.
In the A-549 adenocarcinoma context, ANKRD26 knockout is hypothesized to relieve repression of MYC and BCL2L1, enhancing cell cycle progression and survival while potentially modulating MPL expression. This model enables dissection of ANKRD26??s contribution to lung tumor cell behavior, including growth, migration, and invasion, and provides a platform for exploring crosstalk between thrombopoietin signaling and solid tumorigenesis. The system may also reveal conserved regulatory mechanisms shared between hematopoietic and epithelial tumor suppressor networks.
This polyclonal knockout cell population is suited for detailed functional genomics studies. Researchers can validate target disruption via Western blotting and RT-qPCR, and assess transcriptional consequences using RNA-seq. Phenotypic analyses may include cell proliferation and colony formation assays, wound healing, transwell invasion, flow cytometric cell cycle profiling, and Annexin V apoptosis detection. Drug sensitivity screening can be integrated to investigate context-dependent therapeutic vulnerabilities. For further technical details, please contact Ascent Research.
